The hepatitis B birth dose is a single vaccine injection given to a baby as soon as possible after delivery, ideally within 24 hours, and it is back in the news because a newborn vaccine trial in Guinea-Bissau has been halted. The reported halt concerns approval and ethics, and it does not change the evidence on the vaccine. This explainer answers the questions parents and readers are asking: what the hepatitis B birth dose is, why the World Health Organization recommends it, how mother-to-child transmission happens, what the halted study proposed and what it means for families. It is general information and not medical advice.
Hepatitis B birth dose: key takeaways
- The hepatitis B birth dose is the first of a vaccine series, given within 24 hours of birth where possible.
- Its main purpose is to prevent a baby from catching hepatitis B from an infected mother during or soon after delivery.
- WHO recommends it for all infants, followed by at least two more doses.
- The Guinea-Bissau study was halted over approval and ethics, according to its lead researcher; it was not stopped because of a new safety finding.
- Parents with questions about their own child should ask their doctor or nurse.
What the hepatitis B birth dose is
General background: hepatitis B is a virus that infects the liver. The vaccine contains a harmless part of the virus that teaches the immune system to recognise it. The WHO hepatitis B fact sheet says infants should receive a first dose as soon as possible after birth, preferably within 24 hours, then at least two further doses. Starting at birth matters because the protection is aimed at the period when a baby is most at risk of catching the virus from the mother.
Why hepatitis B birth dose timing matters: mother-to-child transmission
General background: a woman with hepatitis B can pass the virus to her baby at birth, often without knowing she is infected. Babies infected this way are far more likely than older children or adults to develop lifelong infection, which can lead to cirrhosis and liver cancer decades later. WHO describes the birth dose as an effective, essential way to prevent this. Reports from the Guinea-Bissau debate say that, without a birth dose, a large majority of exposed babies can become chronically infected, though exact figures depend on the mother’s infection status.
What the halted study proposed
According to published reports, researchers from the Bandim Health Project planned a randomised trial in Guinea-Bissau comparing a hepatitis B birth dose with a first dose at about six weeks. They were reported to want to study broad outcomes such as deaths, hospital stays and skin and neurodevelopmental conditions, and the target enrolment was about 14,000 newborns. We could not open the protocol. The lead researcher has since said the study will not move forward in Guinea-Bissau because the required government approval was not received, and that no children were enrolled.
Why the hepatitis B birth dose study was criticised
The WHO statement of 13 February 2026 on the Guinea-Bissau trial said a no-treatment control arm is acceptable only when no proven intervention exists, and that withholding the birth dose exposes newborns to serious and potentially irreversible harm. WHO also said the protocol assumed possible safety problems without enough credible evidence. Other critics argued that parents who declined to participate would have no chance of the vaccine, which they said undermines free consent. These are the critics’ positions; the researchers, in reports we saw, said neither schedule is dangerous.
Does the halt mean the hepatitis B birth dose is unsafe?
No. The reported reason for the halt is that the required government approval was not obtained and that the design raised ethical questions. Nothing in the reports we reviewed describes a new safety signal. The health minister said the country never agreed to the study, and reports say the government reaffirmed this on 16 October. Reports also say police sealed or seized vaccine doses at the researchers’ offices, and one account says officials stated this did not indicate any quality or safety problem with the vaccines.
Where Guinea-Bissau stands on the hepatitis B birth dose
Reports say about one in five adults in Guinea-Bissau has hepatitis B, that babies currently receive their first dose from about six weeks and that the country decided in 2024 to add a birth dose to its schedule, with introduction planned for 2028. A WHO spokesperson said WHO stands ready to support a national birth dose. One account says Bandim is fundraising to help roll out birth-dose vaccination, and we have not verified that.
What families should know about the hepatitis B birth dose
These points are general. If you are pregnant, ask for a hepatitis B blood test, since knowing your status lets the care team plan for your baby. In many countries newborns receive the birth dose in hospital without any special request, and if it is missed, ask your doctor how soon to catch up. Do not delay or skip a recommended dose because of a news story. The US Centers for Disease Control and Prevention hepatitis B pages have further information on vaccination.
What is not clear
- Whether the disputed ethics letter was ever valid.
- Exactly what happened to the vaccine doses.
- Whether a new study will be proposed.
- How funders will use any money set aside for the study.
Risks and caveats on the hepatitis B birth dose story
- Accounts differ on approval and on the search of the offices.
- Some details come from single reports and are unverified.
- Individual medical decisions belong with a doctor.
- This is general information, not medical advice.
In our assessment, the hepatitis B birth dose remains a well-established way to protect newborns, and the Guinea-Bissau episode is a story about research approval and ethics and not about the vaccine itself. See also Chronic Hepatitis B Treatment: What Hibsago Changes. More in our healthcare services coverage.
What to watch next on the hepatitis B birth dose
- Government and funder statements on next steps.
- Progress toward a national birth dose in Guinea-Bissau.
- Any independent review of the approvals process.
Frequently asked questions
When should the hepatitis B birth dose be given?
As soon as possible after birth, preferably within 24 hours, according to WHO.
Why was the Guinea-Bissau trial stopped?
Its lead researcher said the required government approval was not received; critics and WHO also raised ethical concerns.
Is the hepatitis B vaccine safe for newborns?
WHO describes the birth dose as effective and essential, and the halt does not change that.
How we reported this: we relied on published reports of October 2026, the WHO statement and WHO background pages; we could not open the study protocol. General background is labelled and conflicting accounts are flagged. Last updated: 23 October 2026. This article is news reporting and education and not medical advice.
